There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioCryst (BCRX), Crinetics Pharmaceuticals Inc (CRNX) and Inovio Pharmaceuticals (INO) with bullish sentiments.
BioCryst (BCRX)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on BioCryst, with a price target of $13. The company’s shares closed yesterday at $3.48, close to its 52-week low of $3.10.
Fein said:
“Valuation and risks to achievement of price target. We reiterate our Buy rating and our price target of $13 is based on the following risk-adjusted sum-of-the-parts NPV-DCF: $11.1 for oral HAE prophylactic treatment + $1.1 for oral liquid HAE acute treatment + $0.2 for peramivir + $0.4 in cash. We assume a discount rate of 13.5%.”
According to TipRanks.com, Fein is a 3-star analyst with an average return of 2.0% and a 42.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $13.50.
See today’s analyst top recommended stocks >>
Crinetics Pharmaceuticals Inc (CRNX)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Crinetics Pharmaceuticals Inc today and set a price target of $35. The company’s shares closed yesterday at $26.32.
Tsao noted:
“We reiterate our Buy rating and $35 price target for Crinetics, which is based on our sum-of-the-parts NPV valuation based on each of the company’s ongoing products. Our DCF model utilizes a discount rate of 12.2% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%).”
According to TipRanks.com, Tsao is a 3-star analyst with an average return of 2.0% and a 51.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Revance Therapeutics, Coherus Biosciences, and Radius Health.
Crinetics Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $37.50.
Inovio Pharmaceuticals (INO)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Inovio Pharmaceuticals today and set a price target of $13. The company’s shares closed yesterday at $3.45, close to its 52-week low of $3.02.
Selvaraju wrote:
“We note that Lassa fever is still a serious public health threat in West Africa, and there is currently no licensed vaccine or approved treatment for Lassa fever. Delivered intradermally via CELLECTRA delivery systems, INO-4500 provided 100% protection in non-human primates challenged with a lethal dose of the virus in a preclinical study. With results from the Phase 1 trial, the company plans to advance 2 field study in endemic countries of West Africa in late 2019 or 2020. Assuming positive Phase 2 data, CEPI, local regulatory authorities, and the World Health Organization (WHO) could stockpile INO-4500 for future use throughout the region. In the wake of this update, we reiterate our Buy rating and $13 price target.”
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -1.2% and a 35.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Inovio Pharmaceuticals is a Strong Buy with an average price target of $10.50, implying a 204.3% upside from current levels. In a report issued on May 9, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $12 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
